CD8A and neoplasm: In addition, CD8+ TIL has also been described as a powerful biomarker in discriminating patients with a significantly longer PFS after ICI treatment; this association was strengthened when IS was integrated with tumor PD-L1 expression, suggesting that the combination of these markers could be a reliable biomarker for immunotherapy (74).